Efficacy and Safety of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD) (EXCITE)
This study has been completed.
Sponsor:
Novartis
Information provided by:
Novartis
ClinicalTrials.gov Identifier:
NCT00275821
First received: January 11, 2006
Last updated: February 22, 2011
Last verified: February 2011
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Purpose
The study will test if the efficacy and safety of an alternative dosing regimen is as effective as monthly injections.
Condition | Intervention | Phase |
---|---|---|
Age Related Macular Degeneration |
Drug: Ranibizumab 0.3 mg - 3 times monthly, then quarterly Drug: Ranibizumab 0.5 mg - 3 times monthly, then quarterly Drug: Ranibizumab 0.3 mg monthly |
Phase 3 |
Study Type: | Interventional |
Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Outcomes Assessor) Primary Purpose: Treatment |
Official Title: | A Randomized, Double-masked, Active-controlled, Multi-center Study Comparing the Efficacy and Safety of Ranibizumab Administered as Two Dosing Regimens in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration |
Resource links provided by NLM:
Genetics Home Reference related topics:
age-related macular degeneration
X-linked juvenile retinoschisis
MedlinePlus related topics:
Macular Degeneration
Drug Information available for:
Ranibizumab
U.S. FDA Resources
Further study details as provided by Novartis:
Primary Outcome Measures:
- Mean Change From Baseline in Best-corrected Visual Acuity of the Study Eye at Month 12 [ Time Frame: Baseline to Month 12 ] [ Designated as safety issue: No ]Visual acuity (VA) was assessed in both eyes at each study visit using best correction determined from protocol refraction. VA measurements were taken in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at an initial testing distance of 4 meters.
Secondary Outcome Measures:
- Mean Change From Baseline in the Total Lesion Area of the Study Eye at Month 12 [ Time Frame: Baseline to Month 12 ] [ Designated as safety issue: No ]Fluorescein angiography was conducted in conjunction with color fundus photography at screening and at Months 6 and 12. Investigators used digital fluorescein angiograms to determine presence or absence of choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD).
- Mean Change From Baseline in Retinal Thickness at the Central Point of the Study Eye at Month 12 [ Time Frame: Baseline to Month 12 ] [ Designated as safety issue: No ]Optical Coherence Tomography (OCT) was performed on both eyes at screening and monthly from baseline through Month 12 prior to study drug administration. OCT images were evaluated at the central reading center (CRC) by trained graders and ophthalmologists experienced in clinical trials.
- Mean Change From Baseline in Retinal Thickness at the Central Subfield of the Study Eye at Month 12 [ Time Frame: Baseline to Month 12 ] [ Designated as safety issue: No ]Optical Coherence Tomography (OCT) was performed on both eyes at screening and monthly from baseline through Month 12 prior to study drug administration. OCT images were evaluated at the central reading center (CRC) by trained graders and ophthalmologists experienced in clinical trials.
Enrollment: | 353 |
Study Start Date: | December 2005 |
Study Completion Date: | January 2008 |
Primary Completion Date: | January 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Experimental: Ranibizumab 0.3 mg - 3 times monthly, then quarterly |
Drug: Ranibizumab 0.3 mg - 3 times monthly, then quarterly
Subjects received intravitreal injections (in the study eye) of ranibizumab 0.3 mg over a duration of 12 months. They were treated monthly for 3 consecutive months and then quarterly for the remainder of the study. On those months when ranibizumab was not administered, patients received a sham injection to preserve the masking of the treatment arms.
|
Experimental: Ranibizumab 0.5 mg - 3 times monthly, then quarterly |
Drug: Ranibizumab 0.5 mg - 3 times monthly, then quarterly
Subjects received intravitreal injections (in the study eye) of ranibizumab 0.5 mg over a duration of 12 months. They were treated monthly for 3 consecutive months and then quarterly for the remainder of the study. On those months when ranibizumab was not administered, patients received a sham injection to preserve the masking of the treatment arms.
|
Active Comparator: Ranibizumab 0.3 mg monthly |
Drug: Ranibizumab 0.3 mg monthly
Subjects received monthly intravitreal injections (in the study eye) of ranibizumab 0.5 mg over a duration of 12 months. On those months when ranibizumab was not administered, patients received a sham injection to preserve the masking of the treatment arms.
|
Eligibility
Ages Eligible for Study: | 50 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Patients with primary or recurrent subfoveal CNV secondary to AMD, including those with predominantly classic, minimally classic or occult lesions with no classic component
- Patients who have a BCVA score between 73 and 24 letters, inclusively, in the study eye using ETDRS-like grading charts (approximately 20/40 to 20/320)
Exclusion Criteria:
- Prior treatment in the study eye with verteporfin, external-beam radiation therapy, subfoveal focal laser photocoagulation, vitrectomy, or transpupillary thermotherapy.
- History of submacular surgery or other surgical intervention for AMD in the study eye, glaucoma filtration surgery, corneal transplant surgery.
- Laser photocoagulation (juxtafoveal or extrafoveal) in the study eye within one month preceding Baseline.
Other protocol-defined inclusion/exclusion criteria applied to the study.
Contacts and Locations
More Information
No publications provided
Keywords provided by Novartis:
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on October 16, 2012
No publications provided
Responsible Party: | External Affairs, Novartis |
ClinicalTrials.gov Identifier: | NCT00275821 History of Changes |
Other Study ID Numbers: | CRFB002A2302 |
Study First Received: | January 11, 2006 |
Results First Received: | December 20, 2010 |
Last Updated: | February 22, 2011 |
Health Authority: | Belgium: Directorate general for the protection of Public health: Medicines |
Keywords provided by Novartis:
Age-related macular degeneration, ranibizumab |
Additional relevant MeSH terms:
Macular Degeneration Neovascularization, Pathologic Choroidal Neovascularization Retinal Degeneration Retinal Diseases |
Eye Diseases Metaplasia Pathologic Processes Choroid Diseases Uveal Diseases |
ClinicalTrials.gov processed this record on October 16, 2012